Who are Atripla or Stribild's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TDF/3TC/EFV or DTG or NVP, Switch to Triumeq, Nevirapine, FTC, and Tenofovir, Doravirine, Tenofovir, Lamivudine, Multiple Product PrEP Program, DOR/DTG/3TC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atripla-or-stribild.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Atripla or Stribild — Competitive Intelligence Brief

Atripla or Stribild (Atripla or Stribild) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based) HIV reverse transcriptase, HIV integrase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Atripla or Stribild (Atripla or Stribild) — Fred Hutchinson Cancer Center. Atripla and Stribild are fixed-dose combination antiretroviral drugs that inhibit HIV replication through multiple mechanisms targeting reverse transcriptase and integrase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Atripla or Stribild TARGET	Atripla or Stribild	Fred Hutchinson Cancer Center	marketed	Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based)	HIV reverse transcriptase, HIV integrase
TDF/3TC/EFV or DTG or NVP	TDF/3TC/EFV or DTG or NVP	MU-JHU CARE	marketed	Antiretroviral combination therapy (NRTI + NNRTI or INSTI)	HIV reverse transcriptase, HIV integrase
Switch to Triumeq	Switch to Triumeq	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Antiretroviral combination therapy (NRTI + INSTI)	HIV reverse transcriptase, HIV integrase
Nevirapine, FTC, and Tenofovir	Nevirapine, FTC, and Tenofovir	University of Maryland, Baltimore	marketed	Antiretroviral combination (NNRTI + NRTI + NtRI)	HIV reverse transcriptase, HIV integrase
Doravirine, Tenofovir, Lamivudine	Doravirine, Tenofovir, Lamivudine	Merck Sharp & Dohme LLC	marketed	Antiretroviral combination (NNRTI + NRTIs)	HIV reverse transcriptase, HIV integrase
Multiple Product PrEP Program	Multiple Product PrEP Program	University of Alabama at Birmingham	marketed	Antiretroviral combination therapy (nucleoside/nucleotide reverse transcriptase inhibitors)	HIV reverse transcriptase, HIV integrase
DOR/DTG/3TC	DOR/DTG/3TC	Insel Gruppe AG, University Hospital Bern	marketed	Antiretroviral combination (NNRTI + INSTI + NRTI)	HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI/NNRTI or INSTI-based) class)

Fred Hutchinson Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Atripla or Stribild — Competitive Intelligence Brief. https://druglandscape.com/ci/atripla-or-stribild. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab